These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics. Li N; Wang Y; Deng W; Lin SH Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796 [TBL] [Abstract][Full Text] [Related]
5. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies. Li Y; Liu CF; Rao GW Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology. Bruin MAC; Sonke GS; Beijnen JH; Huitema ADR Clin Pharmacokinet; 2022 Dec; 61(12):1649-1675. PubMed ID: 36219340 [TBL] [Abstract][Full Text] [Related]
7. Current status and progress in using radiolabelled PARP-1 inhibitors for imaging PARP-1 expression in tumours. Wang Q; Zhang J Eur J Med Chem; 2022 Nov; 242():114690. PubMed ID: 36041258 [TBL] [Abstract][Full Text] [Related]
8. The current status of PARP inhibitors in ovarian cancer. McLachlan J; George A; Banerjee S Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873 [TBL] [Abstract][Full Text] [Related]
9. Veliparib: a new therapeutic option in ovarian cancer? Ghisoni E; Giannone G; Tuninetti V; Genta S; Scotto G; Aglietta M; Sangiolo D; Mittica G; Valabrega G Future Oncol; 2019 Jun; 15(17):1975-1987. PubMed ID: 31074636 [TBL] [Abstract][Full Text] [Related]
10. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy]. Schreiber V; Illuzzi G; Héberlé E; Dantzer F Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693 [TBL] [Abstract][Full Text] [Related]
11. A review on mechanisms of resistance to PARP inhibitors. Desai C; Pathak A; Limaye S; Maniar V; Joshi A Indian J Cancer; 2022 Mar; 59(Supplement):S119-S129. PubMed ID: 35343196 [TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology. Ziadeh T; Kourie HR Pharmacogenomics; 2021 Dec; 22(18):1237-1250. PubMed ID: 34729995 [TBL] [Abstract][Full Text] [Related]
13. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside. Turk AA; Wisinski KB Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759 [TBL] [Abstract][Full Text] [Related]
14. PARP-inhibitor potpourri: A comparative review of class safety, efficacy, and cost. Hennes ER; Dow-Hillgartner EN; Bergsbaken JJ; Piccolo JK J Oncol Pharm Pract; 2020 Apr; 26(3):718-729. PubMed ID: 31902284 [TBL] [Abstract][Full Text] [Related]
15. Human mass balance study and metabolite profiling of van Andel L; Zhang Z; Lu S; Kansra V; Agarwal S; Hughes L; Tibben MM; Gebretensae A; Lucas L; Hillebrand MJX; Rosing H; Schellens JHM; Beijnen JH Invest New Drugs; 2017 Dec; 35(6):751-765. PubMed ID: 28303528 [TBL] [Abstract][Full Text] [Related]
17. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer. Zheng F; Zhang Y; Chen S; Weng X; Rao Y; Fang H Biomed Pharmacother; 2020 Mar; 123():109661. PubMed ID: 31931287 [TBL] [Abstract][Full Text] [Related]
18. Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer. Musella A; Bardhi E; Marchetti C; Vertechy L; Santangelo G; Sassu C; Tomao F; Rech F; D'Amelio R; Monti M; Palaia I; Muzii L; Benedetti Panici P Cancer Treat Rev; 2018 May; 66():7-14. PubMed ID: 29605737 [TBL] [Abstract][Full Text] [Related]
19. PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials. Kamel D; Gray C; Walia JS; Kumar V Curr Drug Targets; 2018; 19(1):21-37. PubMed ID: 28699513 [TBL] [Abstract][Full Text] [Related]
20. The DNA damaging revolution. Cetin B; Wabl CA; Gumusay O Crit Rev Oncol Hematol; 2020 Dec; 156():103117. PubMed ID: 33059228 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]